,,ii #aagth ,,congress #ast ,session ,s4 #bcjd ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,june #bd1 #bjba,mr4 ,durbin 7for himself1 ,mr4 ,grassley1 and ,mr4 ,king7 introduced the following bill2 which was read twice and referred to the ,committee on ,finance ,a ,,bill ,to amend title ,,xi of the ,social ,security ,act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information4 #a4 ,short title ,this ,act may be cited as the ,drug-,price ,transparency for ,competition ,act of #bjba or the ,,dtc ,act of #bjba4 #b4 ,findings2 sense of the ,senate 7a7 ,findings ,congress finds the following3 7#a7 ,direct-to-consumer advertising of prescription pharmaceuticals is legally permitted in only #b developed countries1 the ,united ,states and ,new ,zealand4 7#b7 ,in #bjah1 pharmaceutical ad spending exceeded #f1jdf1jjj1jjj1 a #d4h percent increase over #bjag1 resulting in the average ,american seeing #i drug advertisements per day4 7#c7 ,the most commonly advertised medication in the ,united ,states has a list price of more than #f1jjj for a one-month's supply4 7#d7 ,a #bjba ,government ,accountability ,office report found that two-thirds of all direct-to-consumer drug advertising between #bjaf and #bjah was concentrated among #ci brand-name drugs or biological products1 about half of which were recently approved by the ,food and ,drug ,administration4 7#e7 ,according to a #bjaa ,congressional ,budget ,office report1 pharmaceutical manufacturers advertise their products directly to consumers in an attempt to boost demand for their products and thereby raise the price that consumers are willing to pay1 increase the quantity of drugs sold1 or achieve some combination of the two4 7#f7 ,studies1 including a #bjab systematic review published in the ,annual ,review of ,public ,health1 a #bjje randomized trial published in the ,journal of the ,american ,medical ,association1 and a #bjjd survey published in ,health ,affairs1 show that patients are more likely to ask their doctor for a specific medication and for the doctor to write a prescription for it1 if a patient has seen an advertisement for such medication1 even if such medication is not the most clinically appropriate for the patient or if a lower-cost generic medication may be available4 7#g7 ,according to a #bjaa ,congressional ,budget ,office report1 the average number of prescriptions written for newly approved brand-name drugs with direct-to-consumer advertising was #i times greater than the average number of prescriptions written for newly approved brand-name drugs without direct-to-consumer advertising4 7#h7 ,the ,centers for ,medicare ,medicaid ,services is the single largest drug payer in the ,united ,states4 ,between #bjaf and #bjah1 #eh percent of the #efj1jjj1jjj1jjj in ,medicare drug spending was for advertised drugs1 and in #bjah alone1 the #bj most advertised drugs on television cost ,medicare and ,medicaid a combined #cd1jjj1jjj1jjj4 7#i7 ,a #bjba ,government ,accountability ,office report found that direct-to-consumer advertising may have contributed to increases in ,medicare beneficiary use and spending among certain drugs4 7#aj7 ,the ,american ,medical ,association has passed resolutions supporting the requirement for price transparency in any direct-to-consumer advertising1 stating that such advertisements on their own inflate demand for new and more expensive drugs1 even when these drugs may not be appropriate4 7#aa7 ,a #bjai study published in the ,journal of the ,american ,medical ,association found that health care consumers dramatically underestimate their out-of-pocket costs for certain expensive medications1 but once they learn the wholesale acquisition cost 7in this section referred to as the ,,wac7 of the product1 they are far better able to approximate their out-of-pocket costs4 7#ab7 ,approximately half of ,americans have high-deductible health plans1 under which they often pay the list price of a drug until their insurance deductible is met4 ,all of the top ,medicare prescription drug plans use coinsurance rather than fixed-dollar copayments for medications on nonpreferred drug tiers1 exposing beneficiaries to ,,wac prices4 7#ac7 ,section #aai of division ,,cc of the ,consolidated ,appropriations ,act1 #bjba 7,public ,law #aaf-bfj7 requires the ,secretary of ,health and ,human ,services to increase the use of real-time benefit tools to lower beneficiary costs4 ,however1 there still remains a lack of available pricing tools so patients may not learn of their medication's cost until after being given a prescription for the medication4 ,a #bjac study published in ,the ,oncologist found that one-quarter of all cancer patients chose not to fill a prescription due to cost4 7#ad7 ,the ,federal ,government already exercises its authority to oversee certain aspects of direct-to-consumer drug advertising1 including required disclosures of information related to side effects1 contraindications1 and effectiveness4 7b7 ,sense of ,congress ,it is the sense of ,congress that-- 7#a7 a lack of transparency in pricing for pharmaceuticals has led to a lack of competition for such pharmaceuticals1 as evidenced by a finding by the ,department of ,health and ,human ,services that ,consumers of pharmaceuticals are currently missing information that consumers of other products can more readily access1 namely the list price of the product1 which acts as a point of comparison when judging the reasonableness of prices offered for potential substitute products 7#hd ,fed4 ,reg4 #bjgce72 7#b7 in an age where price information is ubiquitous1 the prices of pharmaceuticals remain shrouded in secrecy and limited to those who subscribe to expensive drug price reporting services1 which typically include pharmaceutical manufacturers or other health care industry entities and not the general public2 7#c7 greater insight and transparency into drug prices will help consumers know if they can afford to complete a course of therapy before deciding to initiate that course of therapy2 7#d7 price shopping is the mark of rational economic behavior1 and markets operate more efficiently when consumers have relevant information about a product1 including its price1 before making an informed decision about whether to buy that product2 7#e7 providing consumers with basic price information may result in the selection of lesser cost alternatives1 all else being equal relative to the patient's care1 and is integral to providing adequate competition in the market2 7#f7 the ,,wac is a factual1 objective1 and uncontroversial definition for the list price of a medication1 in that it is defined in statute1 reflects an understood place in the supply chain1 and is at the sole discretion of the manufacturer to set2 7#g7 there is a governmental interest in ensuring that consumers who seek to purchase pharmaceuticals for purposes of promoting their health and safety understand the objective list price of any pharmaceutical that they are encouraged through advertisements to purchase1 which allows consumers to make informed purchasing decisions2 and 7#h7 there is a governmental interest in mitigating wasteful expenditures and promoting the efficient administration of the ,medicare program by slowing the growth of ,federal spending on prescription drugs4 #c4 ,requirement that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information ,part ,a of title ,,xi of the ,social ,security ,act is amended by adding at the end the following new section3 #aaej;,d4 ,requirement that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information 7a7 ,in general ,the ,secretary shall require that each direct-to-consumer advertisement for a prescription drug or biological product for which payment is available under title ,,xviii or ,,xix includes an appropriate disclosure of pricing information with respect to the drug or product4 7b7 ,appropriate disclosure of pricing information ,for the purposes of subsection 7a71 an appropriate disclosure of pricing information1 with respect to a prescription drug or biological product-- 7#a7 shall include a disclosure of the wholesale acquisition cost 7as defined in section #ahdg;,a7c77#f77;,b77 for a #cj-;day supply of 7or1 if applicable1 a typical course of treatment for7 such drug or product2 7#b7 shall be presented clearly and conspicuously1 as appropriate for the medium of the advertisement2 and 7#c7 may include additional qualitative or quantitative information regarding the price of such drug or product explaining that certain patients may pay a different amount depending on their insurance coverage4 7c7 ,enforcement ,any person who violates the requirement of this section may be subject to a civil money penalty of not more than #ajj1jjj for each such violation or to another enforcement mechanism determined by the ,secretary4 ,any civil money penalty shall be imposed and collected in the same manner as civil money penalties under subsection 7a7 of section #aabh;,a are imposed and collected under that section4 7d7 ,regulations ,the ,secretary1 acting through the ,administrator of the ,centers for ,medicare ,medicaid ,services1 shall promulgate regulations to carry out this section4 ,such regulations shall determine the components of the requirement under this section1 including the forms of advertising1 the manner of disclosure1 the appropriate sanctions1 and the appropriate disclosure of pricing information4 4